Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azoles and AIDS.

R A Larsen1

  • 1Department of Medicine, University of Southern California Medical Center, Los Angeles.

The Journal of Infectious Diseases
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

New antifungal azoles, like fluconazole, offer improved treatment for opportunistic infections in AIDS patients. While cure is rare, controlling infections and improving quality of life are key goals for human immunodeficiency virus (HIV) management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-derived Coccidioides immitis fungemia in solid organ transplant recipients.

Transplant infectious disease : an official journal of the Transplantation Society·2011
Same author

Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients.

International journal of STD & AIDS·2011
Same author

Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome.

Antimicrobial agents and chemotherapy·2011
Same author

Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients.

HIV medicine·2009
Same author

Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2008
Same author

Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2007
Same journal

NET-inducing ability of Cutibacterium acnes clinical isolates is associated with pathogenicity in acne vulgaris.

The Journal of infectious diseases·2026
Same journal

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

The Journal of infectious diseases·2026
Same journal

Monitoring HLA-A2-restricted T cell responses and BCLA-specific serostatus during human latent Toxoplasma gondii infection suggests the implication of CD8+ T cells in parasite containment.

The Journal of infectious diseases·2026
Same journal

Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

The Journal of infectious diseases·2026
Same journal

Type 3 fimbrial regulation underpins anti-MrkA immunotherapeutic efficacy in experimental Klebsiella pneumoniae infection.

The Journal of infectious diseases·2026
Same journal

Rationalising heterogeneity in Staphylococcus aureus bacteraemia: current progress and future goals.

The Journal of infectious diseases·2026
See all related articles

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • HIV/AIDS Therapeutics

Background:

  • Opportunistic infections in AIDS patients require evolving treatment strategies.
  • New antifungal drugs and updated studies on existing ones are rapidly changing clinical practice.
  • Patient response and treatment endpoints differ significantly in human immunodeficiency virus (HIV) infected individuals.

Purpose of the Study:

  • To review current recommendations for azole antifungal use in patients with advanced HIV infection.
  • To discuss the efficacy and toxicity of fluconazole and amphotericin for mycoses in HIV patients.
  • To address the controversial use of 5-fluorocytosine (5FC) in combination therapy.

Main Methods:

  • Review of current clinical recommendations and available data on azole antifungals.

Related Experiment Videos

  • Comparison of therapeutic responses and end points in HIV-infected patients versus other populations.
  • Evaluation of specific treatment regimens for cryptococcal meningitis in advanced HIV.

    • Main Results:

    • Azoles, particularly fluconazole, are valuable additions to the antifungal armamentarium for HIV patients.
    • Amphotericin may offer an initial advantage in treating severe cryptococcal meningitis in sicker patients.
    • Fluconazole presents a less toxic and more easily administered oral option, potentially as effective as amphotericin.
    • The addition of 5FC to amphotericin therapy is debated due to increased bone marrow toxicity without clear efficacy benefits.

    Conclusions:

    • Controlling mycoses to improve quality of life is a realistic and important goal in HIV treatment.
    • Fluconazole is a significant advancement, offering a favorable toxicity and administration profile.
    • Treatment decisions for severe fungal infections in advanced HIV require careful consideration of drug efficacy, toxicity, and patient-specific factors.